Table 3 Univariate analysis of survival
From: RASSF1A hypermethylation in pretreatment serum DNA of neuroblastoma patients: a prognostic marker
Characteristic | Hazard ratio | 95% CI | P -value |
|---|---|---|---|
Age at diagnosis | |||
<12 months | Reference | ||
⩾12 months | 23.6 | 3.1–181.9 | 0.002 |
Sex | |||
Male | Reference | ||
Female | 1.0 | 0.3–3.0 | 0.983 |
Stage | |||
1/2/3/4S | Reference | ||
4 | 19.8 | 4.4–89.5 | <0.001 |
MYCN | |||
Non-amplified | Reference | ||
Amplified | 8.2 | 2.7–24.7 | <0.001 |
Serum RASSF1A | |||
Unmethylated | Reference | ||
Methylated | 9.2 | 2.8–30.1 | <0.001 |
